INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 415m ago
HOUSE PTR15m ago
SEC 13F15m ago
ROBINHOOD CHAIN15m ago
SEC FORM 4/Grant or awardVerified data

Goodrich Katherine reported TARS

Director · Tarsus Pharmaceuticals, Inc. · Tarsus Pharmaceuticals, Inc. — Stock Option (right to buy)

Side
A
Value
—
Shares
3,837
Price
—
Executed
Jun 25, 2026
Disclosed
Jun 29, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 25 executedJun 29, 2026 disclosed

TARS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
5/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TARS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    CN
    Clase NeeraChief Commercial Officer
    TARSTarsus Pharmaceuticals, Inc.
    Grant or award
    		A—
    6,678 sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CN
    Clase NeeraChief Commercial Officer
    TARSTarsus Pharmaceuticals, Inc.
    Grant or award
    		A—
    10.6K sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    27
    NS
    Neervannan SeshadriChief Operating Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$388K
    4,564 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    35
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$485K
    5,386 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    32
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$143K
    1,590 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    20
    AR
    Azamian Bobak R.Director, President/CEO and Board Chair
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$265K
    2,900 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    28
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$135K
    1,590 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    31
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$458K
    5,387 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    20
    AR
    Azamian Bobak R.Director, President/CEO and Board Chair
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$641K
    7,100 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    9
    GD
    Goldberg Andrew D.Director
    TARSTarsus Pharmaceuticals, Inc.
    Grant or award
    		A—
    2,417 sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    GD
    Goldberg Andrew D.Director
    TARSTarsus Pharmaceuticals, Inc.
    Grant or award
    		A—
    3,837 sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    5
    GK
    Goodrich KatherineDirector
    TARSTarsus Pharmaceuticals, Inc.
    Grant or award
    		A—
    2,417 sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    18
    AR
    Azamian Bobak R.Director, President/CEO and Board Chair
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$281K
    4,582 sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    18
    AR
    Azamian Bobak R.Director, President/CEO and Board Chair
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$335K
    5,418 sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    25
    GK
    Goodrich KatherineDirector
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$183K
    2,954 sh
    		Jun 15, 2026Jun 17, 2026
    traded Jun 15, 2026
    		+2dSEC FORM 4

    Evidence

    21
    GK
    Goodrich KatherineDirector
    TARSTarsus Pharmaceuticals, Inc.
    Option exercise
    		M—
    2,954 sh
    		Jun 12, 2026Jun 16, 2026
    traded Jun 12, 2026
    		+4dSEC FORM 4

    Evidence

    9
    GK
    Goodrich KatherineDirector
    TARSTarsus Pharmaceuticals, Inc.
    Option exercise
    		M—
    2,954 sh
    		Jun 12, 2026Jun 16, 2026
    traded Jun 12, 2026
    		+4dSEC FORM 4

    Evidence

    46
    WB
    Wahl BryanGeneral Counsel
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale
    		SELL$284K
    4,084 sh
    		Mar 17, 2026Mar 19, 2026
    traded Mar 17, 2026
    		+2dSEC FORM 4

    Evidence

    42
    WC
    Whitfield Dianne C.Chief Human Resources Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale
    		SELL$280K
    4,071 sh
    		Mar 18, 2026Mar 19, 2026
    traded Mar 18, 2026
    		+1dSEC FORM 4

    Evidence

    36
    LY
    Lin Elizabeth YeuChief Medical Officer
    TARSTarsus Pharmaceuticals, Inc.
    Open-market sale
    		SELL$26K
    375 sh
    		Mar 17, 2026Mar 19, 2026
    traded Mar 17, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002044770-26-000008
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 25, 2026
    Published
    Jun 29, 2026
    Ingested by INSIDER
    Nov 5, 03:50 UTC
    Last re-read
    Nov 5, 03:50 UTC

    Extracted facts

    Filer
    Goodrich Katherine
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Tarsus Pharmaceuticals, Inc. — Stock Option (right to buy)
    Ticker
    TARS
    Shares
    3,837
    Price per share
    $0
    Execution date (reported)
    Jun 25, 2026
    Owned after transaction
    3,837 shares
    Days from execution to publication
    4

    What this establishes

    Goodrich Katherine filed this Form 4 reporting a grant or award of TARS on Jun 25, 2026. It became public on Jun 29, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Goodrich Katherinecik:0002044770
    Issuer
    Tarsus Pharmaceuticals, Inc.cik:0001819790

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.